Table 2.
Prevalence of weight loss among patients with motor complications and receiving dopaminergic therapies.
| Motor complications / dopaminergic therapies |
WL | ||
|---|---|---|---|
| Yes | No | ||
| n (%) | n (%) | p value | |
| Wearing Off (n= 91) | 55 (60.4) | 36 (39.6) | < 0.001 |
|
| |||
| DK (n= 63) | 41 (65.1) | 22 (34.9) | <0.001 |
|
| |||
| FOG (n= 49) | 34 (69.4) | 15 (30.6) | < 0.001 |
|
| |||
| Levodopa (n=110) | 61 (55.5) | 49 (44.5) | 0.003 |
|
| |||
| DA (n= 91) | 48 (52.7) | 43 (47.3) | ns |
PD= Parkinson's disease; WL= weight loss; DK= dyskinesias; DA= dopamine agonists; ns= not significant; n= number of cases